Shots:
- The P-III (TRuE-AD4) study assessed Incyte‘s Opzelura cream (BID) vs vehicle in 241 adults with mod. AD who had an inadequate response, intolerance, or contraindication to topical corticosteroids (TCSs) & calcineurin inhibitors (TCIs); data presented at EADV’26
- As previously reported, the study met its co-1EPs, with 83.5% pts achieving EASI75 & 74.4% reaching IGA-TS, while 74.3% pts had ≥4-point improvement in Itch NRS, showing itch relief at Wk. 8
- Among pts achieving EASI50 at Wk. 8, 84.3% of those treated with Opzelura completed treatment through Wk. 24, with sustained efficacy incl. EASI75 in 84.3%, IGA-TS in 70.6%, low mean affected BSA (2.5% at Wk. 8 & 24), & durable itch relief in 64.7% through Wk. 24. Data supports Type-II variation application in EU, with decision expected in H1’26
Ref: Businesswire | Image: Incyte |Press Release
Related News: Incyte’s Zynyz Receives the EC Approval to Treat Squamous Cell Carcinoma of the Anal Canal (SCAC)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
